Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Hydrocodone | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Magnesium sulfate | The therapeutic efficacy of Cinchocaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Cinchocaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Mirtazapine | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Orphenadrine | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Pramipexole | Cinchocaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Cinchocaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Cinchocaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Cinchocaine. |
| Sodium oxybate | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Thalidomide | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine. |
| Dipyridamole | The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Dipyridamole. |
| Irinotecan | The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Cinchocaine. |
| Ephedrine | Cinchocaine may increase the neuromuscular blocking activities of Ephedrine. |
| Bambuterol | Cinchocaine may increase the neuromuscular blocking activities of Bambuterol. |
| Clevidipine | Cinchocaine may increase the neuromuscular blocking activities of Clevidipine. |
| Sar9, Met (O2)11-Substance P | Cinchocaine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P. |
| Mirabegron | Cinchocaine may increase the neuromuscular blocking activities of Mirabegron. |
| Moxisylyte | Cinchocaine may increase the neuromuscular blocking activities of Moxisylyte. |
| Propacetamol | Cinchocaine may increase the neuromuscular blocking activities of Propacetamol. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Procaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Cocaine. |
| Trimethaphan | Cinchocaine may increase the neuromuscular blocking activities of Trimethaphan. |
| Doxacurium | Cinchocaine may increase the neuromuscular blocking activities of Doxacurium. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloroprocaine. |
| Tubocurarine | Cinchocaine may increase the neuromuscular blocking activities of Tubocurarine. |
| Aclidinium | Cinchocaine may increase the neuromuscular blocking activities of Aclidinium. |
| Butyrylthiocholine | Cinchocaine may increase the neuromuscular blocking activities of Butyrylthiocholine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Oxybuprocaine. |
| Benzonatate | Cinchocaine may increase the neuromuscular blocking activities of Benzonatate. |
| Succinylcholine | The metabolism of Succinylcholine can be decreased when combined with Cinchocaine. |
| Ethanol | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone. |
| Sertraline | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Alaproclate. |
| Technetium Tc-99m tilmanocept | Cinchocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Mecamylamine | The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Cinchocaine. |
| Amantadine | The therapeutic efficacy of Amantadine can be decreased when used in combination with Cinchocaine. |
| Pentolinium | The therapeutic efficacy of Pentolinium can be decreased when used in combination with Cinchocaine. |
| Fenoterol | The therapeutic efficacy of Fenoterol can be decreased when used in combination with Cinchocaine. |
| Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione | The therapeutic efficacy of Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione can be decreased when used in combination with Cinchocaine. |
| Agmatine | The therapeutic efficacy of Agmatine can be decreased when used in combination with Cinchocaine. |
| Esmolol | Cinchocaine may increase the bradycardic activities of Esmolol. |
| Betaxolol | Cinchocaine may increase the bradycardic activities of Betaxolol. |
| Metoprolol | Cinchocaine may increase the bradycardic activities of Metoprolol. |
| Atenolol | Cinchocaine may increase the bradycardic activities of Atenolol. |
| Timolol | Cinchocaine may increase the bradycardic activities of Timolol. |
| Sotalol | Cinchocaine may increase the bradycardic activities of Sotalol. |
| Propranolol | Cinchocaine may increase the bradycardic activities of Propranolol. |
| Labetalol | Cinchocaine may increase the bradycardic activities of Labetalol. |
| Bisoprolol | Cinchocaine may increase the bradycardic activities of Bisoprolol. |
| Alprenolol | Cinchocaine may increase the bradycardic activities of Alprenolol. |
| Pindolol | Cinchocaine may increase the bradycardic activities of Pindolol. |
| Carvedilol | Cinchocaine may increase the bradycardic activities of Carvedilol. |
| Propafenone | Cinchocaine may increase the bradycardic activities of Propafenone. |
| Acebutolol | Cinchocaine may increase the bradycardic activities of Acebutolol. |
| Nadolol | Cinchocaine may increase the bradycardic activities of Nadolol. |
| Bevantolol | Cinchocaine may increase the bradycardic activities of Bevantolol. |
| Practolol | Cinchocaine may increase the bradycardic activities of Practolol. |
| Penbutolol | Cinchocaine may increase the bradycardic activities of Penbutolol. |
| Oxprenolol | Cinchocaine may increase the bradycardic activities of Oxprenolol. |
| Dexpropranolol | Cinchocaine may increase the bradycardic activities of Dexpropranolol. |
| Celiprolol | Cinchocaine may increase the bradycardic activities of Celiprolol. |
| Nebivolol | Cinchocaine may increase the bradycardic activities of Nebivolol. |
| Bufuralol | Cinchocaine may increase the bradycardic activities of Bufuralol. |
| Bopindolol | Cinchocaine may increase the bradycardic activities of Bopindolol. |
| Bupranolol | Cinchocaine may increase the bradycardic activities of Bupranolol. |